Show simple item record

dc.contributor.authorBernatsky, Sasha
dc.contributor.authorRamsey-Goldman, Rosalind
dc.contributor.authorUrowitz, Murray B
dc.contributor.authorHanly, John G
dc.contributor.authorGordon, Caroline
dc.contributor.authorPetri, Michelle A
dc.contributor.authorGinzler, Ellen M
dc.contributor.authorWallace, Daniel J
dc.contributor.authorBae, Sang-Cheol
dc.contributor.authorRomero-Diaz, Juanita
dc.contributor.authorDooley, Mary Anne
dc.contributor.authorPeschken, Christine A
dc.contributor.authorIsenberg, David A
dc.contributor.authorRahman, Anisur
dc.contributor.authorManzi, Susan
dc.contributor.authorJacobsen, Søren
dc.contributor.authorLim, S Sam
dc.contributor.authorvan Vollenhoven, Ronald
dc.contributor.authorNived, Ola
dc.contributor.authorKamen, Diane L
dc.contributor.authorAranow, Cynthia
dc.contributor.authorRuiz-Irastorza, Guillermo
dc.contributor.authorSánchez-Guerrero, Jorge
dc.contributor.authorGladman, Dafna D
dc.contributor.authorFortin, Paul R
dc.contributor.authorAlarcón, Graciela S
dc.contributor.authorMerrill, Joan T
dc.contributor.authorKalunian, Kenneth C
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.authorSteinsson, Kristjan
dc.contributor.authorZoma, Asad
dc.contributor.authorAskanase, Anca
dc.contributor.authorKhamashta, Munther A
dc.contributor.authorBruce, Ian
dc.contributor.authorInanc, Murat
dc.contributor.authorClarke, Ann E
dc.date.accessioned2023-01-11T20:07:53Z
dc.date.available2023-01-11T20:07:53Z
dc.date.issued2021-10-12
dc.identifier.citationBernatsky S, Ramsey-Goldman R, Urowitz MB, Hanly JG, Gordon C, Petri MA, Ginzler EM, Wallace DJ, Bae SC, Romero-Diaz J, Dooley MA, Peschken CA, Isenberg DA, Rahman A, Manzi S, Jacobsen S, Lim SS, van Vollenhoven R, Nived O, Kamen DL, Aranow C, Ruiz-Irastorza G, Sánchez-Guerrero J, Gladman DD, Fortin PR, Alarcón GS, Merrill JT, Kalunian KC, Ramos-Casals M, Steinsson K, Zoma A, Askanase A, Khamashta MA, Bruce I, Inanc M, Clarke AE. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 Dec;73(12):1789-1795. doi: 10.1002/acr.24425. Epub 2021 Oct 12. PMID: 32813314; PMCID: PMC7892637.en_US
dc.identifier.eissn2151-4658
dc.identifier.doi10.1002/acr.24425
dc.identifier.pmid32813314
dc.identifier.urihttp://hdl.handle.net/20.500.12648/8094
dc.description.abstractTo assess cancer risk factors in incident systemic lupus erythematosus (SLE).
dc.description.abstractClinical variables and cancer outcomes were assessed annually among incident SLE patients. Multivariate hazard regression models (overall risk and most common cancers) included demographic characteristics and time-dependent medications (corticosteroids, antimalarial drugs, immunosuppressants), smoking, and the adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000 score.
dc.description.abstractAmong 1,668 patients (average 9 years follow-up), 65 cancers occurred: 15 breast, 10 nonmelanoma skin, 7 lung, 6 hematologic, 6 prostate, 5 melanoma, 3 cervical, 3 renal, 2 each gastric, head and neck, and thyroid, and 1 each rectal, sarcoma, thymoma, and uterine cancers. Half of the cancers (including all lung cancers) occurred in past/current smokers, versus one-third of patients without cancer. Multivariate analyses indicated that overall cancer risk was related primarily to male sex and older age at SLE diagnosis. In addition, smoking was associated with lung cancer. For breast cancer risk, age was positively associated and antimalarial drugs were negatively associated. Antimalarial drugs and higher disease activity were also negatively associated with nonmelanoma skin cancer risk, whereas age and cyclophosphamide were positively associated. Disease activity was associated positively with hematologic and negatively with nonmelanoma skin cancer risk.
dc.description.abstractSmoking is a key modifiable risk factor, especially for lung cancer, in SLE. Immunosuppressive medications were not clearly associated with higher risk except for cyclophosphamide and nonmelanoma skin cancer. Antimalarials were negatively associated with breast cancer and nonmelanoma skin cancer risk. SLE activity was associated positively with hematologic cancer and negatively with nonmelanoma skin cancer. Since the absolute number of cancers was small, additional follow-up will help consolidate these findings.
dc.language.isoenen_US
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/10.1002/acr.24425en_US
dc.rights© 2020, American College of Rheumatology.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleCancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications.en_US
dc.typeArticle/Reviewen_US
dc.source.journaltitleArthritis care & researchen_US
dc.source.volume73
dc.source.issue12
dc.source.beginpage1789
dc.source.endpage1795
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited States
dc.source.countryUnited Kingdom
dc.source.countryUnited States
dc.description.versionAMen_US
refterms.dateFOA2023-01-11T20:07:53Z
html.description.abstractTo assess cancer risk factors in incident systemic lupus erythematosus (SLE).
html.description.abstractClinical variables and cancer outcomes were assessed annually among incident SLE patients. Multivariate hazard regression models (overall risk and most common cancers) included demographic characteristics and time-dependent medications (corticosteroids, antimalarial drugs, immunosuppressants), smoking, and the adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000 score.
html.description.abstractAmong 1,668 patients (average 9 years follow-up), 65 cancers occurred: 15 breast, 10 nonmelanoma skin, 7 lung, 6 hematologic, 6 prostate, 5 melanoma, 3 cervical, 3 renal, 2 each gastric, head and neck, and thyroid, and 1 each rectal, sarcoma, thymoma, and uterine cancers. Half of the cancers (including all lung cancers) occurred in past/current smokers, versus one-third of patients without cancer. Multivariate analyses indicated that overall cancer risk was related primarily to male sex and older age at SLE diagnosis. In addition, smoking was associated with lung cancer. For breast cancer risk, age was positively associated and antimalarial drugs were negatively associated. Antimalarial drugs and higher disease activity were also negatively associated with nonmelanoma skin cancer risk, whereas age and cyclophosphamide were positively associated. Disease activity was associated positively with hematologic and negatively with nonmelanoma skin cancer risk.
html.description.abstractSmoking is a key modifiable risk factor, especially for lung cancer, in SLE. Immunosuppressive medications were not clearly associated with higher risk except for cyclophosphamide and nonmelanoma skin cancer. Antimalarials were negatively associated with breast cancer and nonmelanoma skin cancer risk. SLE activity was associated positively with hematologic cancer and negatively with nonmelanoma skin cancer. Since the absolute number of cancers was small, additional follow-up will help consolidate these findings.
dc.description.institutionSUNY Downstateen_US
dc.description.departmentRheumatologyen_US
dc.description.degreelevelN/Aen_US
dc.identifier.journalArthritis care & research


Files in this item

Thumbnail
Name:
nihms-1630079.pdf
Size:
91.94Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2020, American College of Rheumatology.
Except where otherwise noted, this item's license is described as © 2020, American College of Rheumatology.